The ADAM10 Knockout CAL-27 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the CAL-27 human oral squamous cell carcinoma line. This product provides a heterogeneous loss-of-function model for ADAM10, eliminating the need for single-cell cloning while enabling robust investigation of ADAM10-dependent processes. CRISPR/Cas9-mediated gene disruption abrogates ADAM10 protein expression, allowing dissection of its roles in ectodomain shedding and signaling.
CAL-27 cells originate from a human tongue squamous cell carcinoma and serve as a well-characterized epithelial model of oral cancer progression, invasion, and metastasis. Their aggressive phenotype, marked by dysregulated adhesion and motility, makes them an appropriate cellular context for studying the impact of ADAM10 disruption on tumorigenic properties.
ADAM10 encodes a transmembrane disintegrin metalloproteinase that functions as a sheddase for numerous substrates, including Notch receptors, E-cadherin, APP, TNF??, and HB-EGF. Cleavage of Notch1 generates the NICD, which translocates to the nucleus and transcriptionally activates HES1 and other targets, driving proliferation and stemness. Shedding of E-cadherin yields soluble fragments that destabilize adherens junctions and promote migration. ADAM10 activity is regulated by upstream signals such as retinoic acid, calcium influx, ATF4, and SRC kinase, and it interacts with tetraspanins TSPAN12/TSPAN14, calmodulin, and ADAM17. Loss of ADAM10 in these polyclonal cells abrogates substrate cleavage, thereby disrupting Notch and EGFR pathway crosstalk, reducing soluble effector generation, and altering cell adhesion and migratory capacity.
Within the CAL-27 oral cancer background, ADAM10 knockout is expected to attenuate tumorigenic potential by simultaneously impairing Notch signaling and stabilizing E-cadherin-mediated adhesion. Diminished NICD levels reduce HES1 and MYC expression, while loss of soluble E-cadherin fragments reinforces cell?Ccell contacts, potentially suppressing invasion. Additionally, impaired release of HB-EGF and soluble TNF?? dampens EGFR and inflammatory signaling, including reduced ERK phosphorylation. Consequently, this model enables detailed analysis of ADAM10??s contribution to oral squamous cell carcinoma progression and metastasis.
Key applications include dissecting Notch/EGFR crosstalk, quantifying migration and invasion using Transwell assays, assessing downstream gene expression by RT-qPCR (e.g., HES1, MYC), and evaluating therapeutic targeting of ADAM10. Researchers can validate knockout effects via western blotting for cleaved substrates, flow cytometry for cell surface E-cadherin, and phospho-ERK analysis. These polyclonal knockout cells are suitable for functional genomics and drug discovery studies. For further information, please contact Ascent Research.
